VRTX
Vertex Pharmaceuticals Incorporated Common Stock
Price performance
Sep 18, 2026About
Company activity
17 events| Time | Ticker | Type | Event | Qty | Price | Value |
|---|---|---|---|---|---|---|
| 09/01 | VRTX | 8-K | Vertex Pharmaceuticals Appoints New Chief Financial Officer | — | — | — |
| 08/03 | VRTX | 8-K | Vertex Pharmaceuticals Announces Acquisition of Crinetics Pharmaceuticals and Reports Q2 2026 Results | — | — | — |
| 07/06 | VRTX | 8-K | Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals for $10B | — | — | — |
| 05/13 | VRTX | 8-K | Vertex Pharmaceuticals Approves 2026 Stock and Option Plan | — | — | — |
| 05/04 | VRTX | 8-K | Vertex Pharmaceuticals Reports Strong Q1 2026 Financial Results and Pipeline Updates | — | — | — |
| 04/29 | VRTX | 8-K | Vertex Pharmaceuticals Director Suketu Upadhyay to Depart Board | — | — | — |
| 03/31 | VRTX | 8-K | Vertex Pharmaceuticals Submits Rolling BLA for Povetacicept to FDA | — | — | — |
| 02/12 | VRTX | 8-K | Vertex Pharmaceuticals Reports Strong Q4 2025 Results and Provides 2026 Guidance | — | — | — |
| 11/03/25 | VRTX | 8-K | Vertex Pharmaceuticals Reports Third Quarter 2025 Financial Results and Revises Full Year Guidance | — | — | — |
| 08/04/25 | VRTX | 8-K | Vertex Pharmaceuticals Reports Strong Q2 2025 Financial Results and Key Business Updates | — | — | — |
| 05/19/25 | VRTX | 8-K | Vertex Pharmaceuticals Announces Additional Stock Repurchase Program | — | — | — |
| 05/14/25 | VRTX | 8-K | Vertex Shareholders Re-elect Board Members and Approve Key Proposals | — | — | — |
| 05/05/25 | VRTX | 8-K | Vertex Pharmaceuticals Reports Q1 2025 Financial Results and Raises Revenue Guidance | — | — | — |
| 03/28/25 | VRTX | 8-K | Vertex Pharmaceuticals Announces Impairment Charge for Discontinued VX-264 Program | — | — | — |
| 02/10/25 | VRTX | 8-K | Vertex Announces Leadership Transition and Reports Q4 2024 Financial Results | — | — | — |
| 12/20/24 | VRTX | 8-K | Vertex Pharmaceuticals Announces FDA Approval for ALYFTREK to Treat Cystic Fibrosis | — | — | — |
| 11/04/24 | VRTX | 8-K | Vertex Pharmaceuticals Raises Full-Year Revenue Guidance After Strong Q3 Performance | — | — | — |
VRTX filing record
Vertex Pharmaceuticals Incorporated Common Stock (VRTX): 17 8-K filings summarized, the most recent on Sep 1, 2026.
What the 8-K filings said
- Sep 1, 2026 · high impact
Vertex Pharmaceuticals Incorporated announced on August 27, 2026, the appointment of Jonathan Poole as its new Executive Vice President and Chief Financial Officer, effective January 1, 2027. Mr. Poole, who has been with the company since 2020, will succeed Charles F. Wagner, Jr., who will continue in his role as…
Vertex Pharmaceuticals Appoints New Chief Financial Officer - Aug 3, 2026 · high impact
Vertex Pharmaceuticals reported a 12% increase in total revenue for the second quarter of 2026, reaching $3.33 billion. The company raised its full-year revenue guidance to $13.1 to $13.2 billion. Vertex also announced the acquisition of Crinetics Pharmaceuticals for $10 billion, which is expected to close in the…
Vertex Pharmaceuticals Announces Acquisition of Crinetics Pharmaceuticals and Reports Q2 2026 Results - Jul 6, 2026 · high impact
Vertex Pharmaceuticals has announced its intention to acquire Crinetics Pharmaceuticals for $10 billion in an all-cash transaction. The acquisition, unanimously approved by the boards of both companies, is expected to close in Q3 2026, pending shareholder approval and other conditions. The deal values Crinetics at $85…
Vertex Pharmaceuticals to Acquire Crinetics Pharmaceuticals for $10B - May 13, 2026 · high impact
Vertex Pharmaceuticals Incorporated's shareholders approved the 2026 Stock and Option Plan, which replaces the 2013 plan, at the company's annual meeting held on May 13, 2026. The meeting also saw the election of ten directors and the ratification of Ernst & Young LLP as the company's independent auditor for the year…
Vertex Pharmaceuticals Approves 2026 Stock and Option Plan - May 4, 2026 · high impact
Vertex Pharmaceuticals Incorporated reported an 8% increase in total revenue for the first quarter of 2026, reaching $2.99 billion. The company reiterated its full-year 2026 financial guidance, expecting total revenue between $12.95 billion and $13.1 billion. Key highlights include the expansion of label eligibility…
Vertex Pharmaceuticals Reports Strong Q1 2026 Financial Results and Pipeline Updates
SEC filings in the last five years
- 36 Form 8-K
- 13 Form 10-Q
- 5 Form 10-K